Second-generation antihistamines: The risk of ventricular arrhythmias

Clinical Therapeutics

Volumn 21, Issue 2, 1999, Pages 281-295

  DuBuske, Lawrence M ^a,b  

^a Brigham and Women's Hospital ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antihistamines; QT interval; Torsades de pointes; Ventricular arrhythmia

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; CETIRIZINE; CYTOCHROME P450 INHIBITOR; FEXOFENADINE; LORATADINE; POTASSIUM CHANNEL; TERFENADINE;

ANIMAL EXPERIMENT; DRUG METABOLISM; DRUG OVERDOSE; ELECTROCARDIOGRAM; FATALITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; LIVER FAILURE; NONHUMAN; QT INTERVAL; REPOLARIZATION; REVIEW; TORSADE DES POINTES;

EID: 0032896891     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88286-7     Document Type: Article

References (58)

1. 1-receptor antagonists. Ann Allergy. 1991;66:5-16.
2. 1-receptor antagonists: Clinical pharmacology. Clin Exp Allergy. 1990;20(Suppl 2):19-24.
3. 3. Azelastine prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc.; 1998:2952-2954.
4. 4. Nolen TM. Sedative effects of antihistamines: Safety, performance, learning, and quality of life. Clin Ther. 1997;19:39-55.
5. 1-receptor antagonist treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1990;86:1000-1003.
6. 1-receptor antagonists. Otolaryngol Head Neck Surg. 1993;109:584-592.
7. 1 antihistamines in chronic urticaria. Ann Allergy. 1993;71:585-591.
8. 8. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
9. 9. Bolstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol. 1993;72:50B-52B.
10. 10. Nightingale SL. From the US Food and Drug Administration. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA. 1992;268:705.
11. 11. US Food and Drug Administration. Important New Safety Information About Hismanal. Rockville, Md: National Press Office; February 9, 1998. Talk Paper.
12. 12. Woosley RL, Chen Y, Freiman JP, et al. Mechanisms of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
13. 13. Grant AO, Whalley DE. Mechanisms of cardiac arrhythmias. In: Topol EJ, ed. Comprehensive Cardiovascular Medicine. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:1669-1684.
14. 14. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-252.
15. 15. Simons KJ, Watson WT, Martin TJ, et al. Diphenhydramine: Pharmacokinetics and pharmacodynamics in elderly adults, young adults and children. J Clin Pharmacol. 1990;30:665-671.
16. 16. Hollister LE. Hydroxyzine hydrochloride: Possible adverse cardiac interactions, Psychopharmacol Commun. 1975;1:61-65.
17. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995;76:110-119.
18. 1 antagonists: Comparative studies with loratadine, terfenadine and sedating antihistamines in guinea pigs. Clin Exp Allergy. 1995;25:974-984.
19. 19. Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneim-Forsch Drug Res. 1996;46:53-58.
20. + channels. J Cardiovasc Pharmacol. 1997;30:42-54.
21. 21. Roden DM. Antiarrhythmic drugs. In: Topol EJ, ed. Comprehensive Cardiovascular Medicine. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:2053-2070.
22. + channels by nonsedating antihistamines. Circulation. 1995;91:2220-2225.
23. 1 receptor blocker cetirizine compared with other second-generation antihistamines, Mol Pharmacol. 1998;54:113-121.
24. 24. Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-deendent enzymes. J Clin Invest. 1983;71:1495-1499.
25. 25. Yun C-H, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P-450 3A(4) in N-dealkylation and c-hydroxylation. Drug Metab Dispos. 1993;21:403-409.
26. 26. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
27. 27. Pohjola-Sintonen S, Viitasalo M, Toivenen L, et al. Torsades de pointes after terfenadine-itraconazole interaction. BMJ. 1993;306:186.
28. 1-receptor antagonists. Ann Allergy. 1987;59:20-24.
29. 29. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsades de pointes, J Formos Med Assoc. 1997;96:144-146.
30. 30. Rao KA, Adlakha A, Verma-Ansil B, et al. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc. 1994;69:589-593.
31. 31. Sakemi H, VanNatta B. Torsades de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J. 1993;125:1436-1438.
32. 32. Data on file. Kenilworth, NJ: Schering-Plough Research Institute, Schering-Plough Inc.; 1998.
33. 33. Yumibe N, Huis K, Chen KJ, et al. Identification of human liver cytochrome P450 involved in the metabolism of loratadine. J Allergy Clin Immunol. 1994;234 (Suppl):A17. Abstract 429.
34. 34. Van Peer A, Crabbé R, Woestenborghs R, et al. Ketoconazole inhibits loratadine metabolism in man. Allergy. 1993;48(Suppl 16):34. Abstract.
35. 35. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations, Clin Pharmacol Ther. 1995;58:269-278.
36. 36. Brannan MD, Affrime MB, Reidenberg P, et al. Evaluation of the pharmacokinetics and electrocardiographic pharmacokinetics of loratadine with concomitant administration of cimetidine. Pharmacotherapy. 1994;14:347. Abstract.
37. 37. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1988;18:84-112.
38. 38. Brannan MD, Reidenberg P, Radwanski E, et al. Evaluation of pharmacokinetic and electrocardiographic parameters following 10 days of concomitant administration of loratadine with ketoconazole. J Clin Pharmacol. 1994;34:1016. Abstract.
39. 39. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther. 1994;56:295-301.
40. 40. Bronsky EA, Meltzer EO, Perhach JL, et al. Cardiac safety of azelastine following 8 weeks of intranasal administration. J Allergy Clin Immunol. 1997;99(Pt 2):S445. Abstract.
41. 41. Morganroth J, Lyness WH, Perhach JL, et al. Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers. J Clin Pharmacol. 1997;37:1065-1072.
42. 42. Russel T, Stolz M, Eller M, et al. Acute and subehronic dose tolerance of fexofenadine HCl in healthy male subjects. In: Program and abstracts of the British Society for Allergy and Clinical Immunology meeting; September 1996; Manchester, England, Abstract P/41.
43. c), In: Program and Abstracts of European Academy of Allergology and Clinical Immunology '97; June 1-4, 1997; Rhodes, Greece. Abstract.
44. 44. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:443-448.
45. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc. 1998;19:135-141.
46. 46. Fexofenadine prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc.; 1998:1189-1190.
47. 47. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet. 1997;349:1322. Letter.
48. 48. Cohen AT. Dangers of non-sedating antihistamines. Lancet. 1997;350:69. Letter.
49. 49. Himmel MH, Honig PK, Worobee AS. Dangers of nonsedating antihistamines. Lancet. 1997;350:69. Letter.
50. 50. 1993 MarketScan databases. Washington, DC: MEDSTAT Group; 1993.
51. 51. National Health Interview Survey (NHIS). Atlanta, Ga: National Center for Health Statistics. Centers for Disease Control and Prevention; 1987.
52. 52. National Health Interview Survey (NHIS). Atlanta, Ga: National Center for Health Statistics. Centers for Disease Control and Prevention; 1989.
53. 53. National Health Interview Survey (NHIS). Atlanta, Ga: National Center for Health Statistics. Centers for Disease Control and Prevention; 1990.
54. 54. Clark JM, Hamer J, Shelton JR, et al. The rhythm of the normal human heart. Lancet. 1976;2:508-512.
55. 55. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population. Detection by 24-hour ambulatory electrocardiography. Chest. 1982;81:302-307.
56. 56. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46:101-110.
57. 57. Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second-generation anti-histamines. Int J Clin Pharmacol Ther. 1998;36:292-300.
58. 58. US Food and Drug Administration. Roche Laboratories Announces Withdrawal of Posicor from the Market. Rockville, Md: National Press Office; June 8, 1998, Talk Paper.